An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma

Exclusion Criteria

• •Known to be allergic to recombinant humanized PD-1 monoclonal antibody drugs and their components
• •Presence of any active autoimmune disease or history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; patients with vitiligo; complete remission of asthma in childhood, no intervention after adulthood can be included; patients with asthma requiring bronchodilators for medical intervention can not be included)
• •Patients are using immunosuppressive agents, or systemic hormone therapy to achieve the purpose of immunosuppression (dose \> 10 mg/day prednisone or other effective hormones), and continue to use 2 times before enrollment
• •Pregnant or lactating women
• •Other malignant tumors have been diagnosed within 5 years before the first use of the study drug, except for effectively treated cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma and/or effectively resected in situ cervical cancer and/or breast cancer
• •Patients prone to infection and poor blood glucose control
• •Incomplete important imaging examination and incomplete record of adverse reactions
• •Previous surgery, chemotherapy, targeted, radiotherapy and immune-related therapy
• •Other conditions that the investigator judges may affect the conduct of the clinical study and the judgment of the study results